Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Mar 2024 · 1 min read
In brief
In brief
Multi-institutional retrospective study of 78 pediatric patients with undifferentiated embryonal sarcoma of the liver treated across 17 North American centers over 30 years. Neoadjuvant chemotherapy achieved >90% tumor necrosis in most cases, with R0 resection being the key prognostic factor for event-free and overall survival.
Written by the GCMD Library team from the article.
Statements in this article
The median age at presentation for undifferentiated embryonal sarcoma of the liver is 9.9 years (interquartile range 7-12 years).
Twenty-seven patients (35%) underwent resection at diagnosis while 47 patients (60%) underwent delayed resection after neoadjuvant chemotherapy.
Eight patients underwent liver transplantation as part of their surgical management.
Neoadjuvant chemotherapy led to a median change in maximum tumor diameter of 1.6 cm (interquartile range 0.0-4.4 cm).
Greater than 90% tumor necrosis was achieved in 79% of patients undergoing delayed resection after neoadjuvant chemotherapy.
R0 resections were accomplished in 63 patients (81% of the cohort).
Metastatic disease at presentation impacts overall survival in univariate analysis.
Completeness of resection impacts both event-free survival and overall survival in univariate analysis.
R0 resection is associated with decreased expected hazards of experiencing an event (hazard ratio 0.14, 95% confidence interval 0.05-0.38) in multivariate analysis.